

ABSTRACT OF THE DISCLOSURE

10044007
SECRET
5 A method of utilizing the chymotrypsin level of an individual as a measure
of the success of secretin, other neuropeptides, and peptides or digestive enzyme
administration to such individuals, and in particular, as a prognosticative of
potential secretin, other neuropeptides, peptides, and digestive enzyme
administration for persons having ADD, ADHD, Autism and other PDD related
disorders. In one aspect, a method for determining the efficacy of secretin, other
neuropeptides, peptides, or digestive enzymes for the treatment of an individual
diagnosed with a pervasive developmental disorder (PDD) comprises obtaining a
sample of feces from an individual, determining a quantitative level of
chymotrypsin present in the sample, and correlating the quantitative level of
chymotrypsin determined to be present in the sample with the PDD to determine
the efficacy of treating the individual with secretin, other neuropeptides, peptides,
or digestive enzyme administration. In another aspect, a therapeutic method for
treating an individual diagnosed with a PDD pervasive developmental disorder
comprises determining the efficacy of secretin, other neuropeptides, peptides, and
digestive enzyme administration for the treatment of the individual based on a
measure of the individual's chymotrypsin level, and administering secretin, other
neuropeptides, peptides, or digestive enzymes to the individual based on the
determination of the measure of the individual's chymotrypsin level.